Sale of RPK (Details) - 12 months ended Dec. 31, 2025 - RPK Biopharma Unipessoal Lda. (“RPK”) [Member] |
USD ($) |
EUR (€) |
|---|---|---|
| Sale of RPK [Line Items] | ||
| Cash consideration | $ (2,000,000) | |
| Net debt (in Euro) | € | € 4,000,000 | |
| Deposits from banks | 500,000 | |
| Aggregate fee | 446,250 | |
| Gain on sale of subsidiary | 198,780 | |
| Gain on discontinued operations | $ (827,620) |
| X | ||||||||||
- Definition The amount of deposit liabilities from banks held by the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. No definition available.
|
| X | ||||||||||
- Definition The gains (losses) recognised in association with the loss of control over a subsidiary, which are attributable to the former controlling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net debt of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|